Clinical significance of the transcription factor (SOX11) expression in the bone marrow of acute myeloid leukemia patients

Table 1 Clinical and laboratory data of the acute myeloid leukemia patients

Parameters		Frequency
Gender, n (%)	Male	61 (59.8)
	Female	41 (40.2)
Age (years)	mean ± SD	42.61 ± 14.7
	Median (IQR)	44 (18-78)
Hb (g/dL)	mean ± SD	7.7 ± 2.1
Platelets (× 109/L)	Median (IQR)	46.5 (4-836)
TLC (× 109/L)	Median (IQR)	37.62 (11.2-488.9)
PB blast	Median (IQR)	30 (0-99)
BM blast	Median (IQR)	49 (0-98)
D14 blasts	Median (IQR)	0 (0-80)
D28 blasts	Median (IQR)	0 (0-80)
BM cellularity, n (%)	Hypocellular	11 (10.8)
	Normocellular	26 (25.5)
	Hypercellular	65 (63.7)
FAB, n (%)	AML-M0	2 (2)
	AML-M1	16 (15.7)
	AML-M2	44 (43.1)
	AML-M3	4 (3.9)
	AML-M4	28 (27.5)
	AML-M5	7 (6.9)
	AML-M6	1 (1.0)
CD34, n (%)	Negative	61 (60)
	Positive	41 (40)
Cytogenetics, n (%)	Normal	65 (64)
	abnormal	37 (36)
Cytogenetics abnormalities, n (%)	Inv 16	9 (8.8)
	t (8;21)	16 (15.7)
	t (15;17)	4 (3.9)
	46xy, del7	4 (3.9)
	46xy, del 8, del 9	1 (1)
	46xy, +8	3 (42.9)
Molecular genetics markers, n (%)
FLT3 ITD, n (%)	Negative	65 (63.7)
	Positive	37 (36.3)
NPM, n (%)	Negative	71 (69.6)
	Positive	31 (30.4)
Response to induction therapy, n (%)	CR	33 (73.3)
	No CR	12 (26.7)
Relapse/refractory, n (%)	Negative	37 (72.5)
	Positive	14 (27.5)
Death, n (%)	Negative	31 (30.4)
	Positive	71 (69.6)
Liver, n (%)	Negative	87 (85.3)
	Positive	15 (14.7)
Spleen, n (%)	Negative	84 (82.4)
	Positive	18 (17.6)
LNs affection, n (%)	Negative	93 (91.2)
	Positive	9 (8.8)

BM: Bone marrow; CR: Complete remission; Hb: Hemoglobin; LNs: Lymph nodes; PB: Peripheral blood; TLC: Total leukocyte count.